TNGX Tango Therapeutics, Inc. Insider Trading

Adam Crystal (TNGX President, R&D) sold 27,000 shares in 2 transactions on 2026-06-01 for $617.6K via scheduled 10b5-1 plan.

Adam Crystal executed 2 separate sales totaling 27,000 shares for $617,571.27 at blended average price $22.87, reducing his non-derivative holdings by 18.9% to 115,743 shares post-transaction. The sales were executed via a pre-arranged 10b5-1 trading plan adopted on 2025-10-27, making this a scheduled transaction rather than a discretionary timing decision. Crystal retains 341,040 shares in stock option holdings (Table II derivative securities). The stock is currently trading at $21.47, down 5.5% over 30 days and down 24.4% from its 52-week high of $28.41, despite a +27.6% gain over 90 days. The company reported zero latest-quarter revenue and annual net income of -$45.5M, though it showed 48.3% annual revenue growth. His prior sales at TNGX have shown mixed outcomes: two recent May sales posted +3.7% and -0.1% 30-day returns, while an April 15 sale yielded -17.8% 30-day performance. The scheduled nature of this transaction removes discretionary timing as an interpretive lens; investors should focus on the composition of remaining holdings (both non-derivative and derivative) relative to the company's unprofitable operating status.

Tango President of R&D buys 27K shares while net-selling 27K in same day; aggressive stock recovery amid steep losses

Crystal Adam, President of R&D at Tango Therapeutics, executed a complex same-day transaction on May 1st: purchasing 27,000 shares while simultaneously selling a nearly equivalent volume. The buy component adds meaningful capital commitment at a time when the stock is trading well below its recent highs after a significant pullback. Critically, this move occurs while the company is unprofitable with substantial annual losses, making Adam's decision to accumulate shares despite weak fundamentals noteworthy. However, the offsetting sell of roughly the same share count within hours raises questions about whether this represents genuine conviction or opportunistic tax-loss harvesting or option exercise mechanics. For a R&D leader at a therapeutics company, the timing and structure of this trade deserve closer scrutiny to understand whether Adam sees value ahead or is simply rebalancing positions.